Fluconazole

• Capsules 150mg (£0.86 = 1 capsule)
• Capsules 50mg (£0.98 = 7 capsules)
• Intravenous infusion 2mg/ml, 25ml bottle, 100ml bottle

Indications

• Vaginal candidiasis
• Oral candidiasis

Itraconazole

• Capsules 100 mg (£4.69 = 15 capsules)
• Oral solution sugar free 50mg/5ml (£53.42 = 150ml)
• Concentrate for intravenous infusion 250mg/25ml

Indications

• Dermatophyte infection

Isavuconazole

• Capsules 100mg
• Powder for concentrate for solution for infusion 200mg vial

Posaconazole

• Oral suspension 40mg/ml
• Gastro-resistant tablets 100mg
• Intravenous infusion 300mg

Notes

1. Tablets not licensed for oropharyngeal candidiasis
2. Where possible, tablets should be used in preference to the suspension because the tablets have a higher bioavailability; the suspension is not interchangeable with the tablets on a milligram-for-milligram basis
3. Healthcare Professional Communication (September 2024): Noxafil (posaconazole) new Gastro-Resistant Powder and Solvent for Oral Suspension not interchangeable with existing Oral Suspension including generics
   1. A new formulation of Noxafil, gastro-resistant powder and solvent for oral suspension (PFS) has been approved for use in children 2 years of age and older.
   2. Noxafil PFS and the existing oral suspension (OS) formulation including generics are not interchangeable.
   3. Substitution between the two formulations can potentially result in over or underdosing, and risks of serious adverse drug reactions or lack of efficacy.
   4. Prescribers should always specify the formulation and dosage for posaconazole on each prescription.

Voriconazole

• Tablets 50mg, 200mg
• Intravenous infusion 200mg